keyword
MENU ▼
Read by QxMD icon Read
search

Prostate multiparametric imaging

keyword
https://www.readbyqxmd.com/read/28935163/optimising-the-diagnosis-of-prostate-cancer-in-the-era-of-multiparametric-magnetic-resonance-imaging-a-cost-effectiveness-analysis-based-on-the-prostate-mr-imaging-study-promis
#1
Rita Faria, Marta O Soares, Eldon Spackman, Hashim U Ahmed, Louise C Brown, Richard Kaplan, Mark Emberton, Mark J Sculpher
BACKGROUND: The current recommendation of using transrectal ultrasound-guided biopsy (TRUSB) to diagnose prostate cancer misses clinically significant (CS) cancers. More sensitive biopsies (eg, template prostate mapping biopsy [TPMB]) are too resource intensive for routine use, and there is little evidence on multiparametric magnetic resonance imaging (MPMRI). OBJECTIVE: To identify the most effective and cost-effective way of using these tests to detect CS prostate cancer...
September 18, 2017: European Urology
https://www.readbyqxmd.com/read/28933973/magnetic-resonance-imaging-in-the-early-detection-of-prostate-cancer-and-review-of-the-literature-on-magnetic-resonance-imaging-stratified-clinical-pathways
#2
Taimur Tariq Shah, Wilson King Lim To, Hashim Uddin Ahmed
With level 1 evidence now available on the diagnostic accuracy of multiparametric magnetic resonance imaging (MRI) we must now utilise this data in developing an MRI-stratified diagnostic pathway for the early detection of prostate cancer. Areas covered: A literature review was conducted and identified seven randomised control trials (RCT's) assessing the diagnostic accuracy of such a pathway against the previously accepted systematic/random trans-rectal ultrasound guided (TRUS) biopsy pathway. The studies were heterogeneous in their design...
September 21, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28927782/development-and-internal-validation-of-prediction-models-for-biochemical-failure-and-composite-failure-after-focal-salvage-high-intensity-focused-ultrasound-for-local-radiorecurrent-prostate-cancer-presentation-of-risk-scores-for-individual-patient-prognoses
#3
Max Peters, Abi Kanthabalan, Taimur T Shah, Neil McCartan, Caroline M Moore, Manit Arya, Jochem R van der Voort van Zyp, Marinus A Moerland, Richard G Hindley, Mark Emberton, Hashim U Ahmed
PURPOSE: Patient selection for focal salvage remains difficult. Therefore, we developed and internally validated prediction models for biochemical failure (BF) and a composite endpoint (CE) following focal salvage high intensity focused ultrasound (HIFU) for radiorecurrent prostate cancer. MATERIALS AND METHODS: A prospective HIFU registry identified 150 cases (November 2006-August 2015). Recurrence was assessed with multiparametric magnetic resonance imaging (MRI) combined with template prostate mapping biopsies, targeted biopsies, or systematic transrectal ultrasound-guided biopsies...
September 15, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28921850/prospective-comparison-of-transperineal-mri-ultrasound-fusion-biopsy-and-transrectal-systematic-biopsy-in-biopsy-na%C3%A3-ve-patients
#4
Angelika Borkowetz, Boris Hadaschik, Ivan Platzek, Marieta Toma, Georgi Torsev, Theresa Renner, Roman Herout, Martin Baunacke, Michael Laniado, Gustavo Baretton, Jan Philipp Radtke, Claudia Kesch, Markus Hohenfellner, Michael Froehner, Heinz-Peter Schlemmer, Manfred Wirth, Stefan Zastrow
OBJECTIVES: To evaluate the value of multiparametric magnetic resonance imaging (mpMRI) for the detection of significant prostate cancer (PCa) and to compare transperineal MRI/ultrasound-fusion biopsy (fusPbx) to conventional transrectal systematic biopsy (sysPbx) in biopsy-naïve patients. PATIENTS AND METHODS: This multicentre, prospective trial investigated biopsy-naïve patients with suspicion of PCa undergoing transperineal fusPbx in combination with transrectal sysPbx (comPbx)...
September 16, 2017: BJU International
https://www.readbyqxmd.com/read/28906339/multiparametric-magnetic-resonance-imaging-of-prostate-cancer-bone-disease-correlation-with-bone-biopsy-histological-and-molecular-features
#5
Raquel Perez-Lopez, Daniel Nava Rodrigues, Ines Figueiredo, Joaquin Mateo, David J Collins, Dow-Mu Koh, Johann S de Bono, Nina Tunariu
OBJECTIVES: The aim of this study was to correlate magnetic resonance imaging (MRI) of castration-resistant prostate cancer (CRPC) bone metastases with histological and molecular features of bone metastases. MATERIALS AND METHODS: Forty-three bone marrow biopsies from 33 metastatic CRPC (mCRPC) patients with multiparametric MRI and documented bone metastases were evaluated. A second cohort included 10 CRPC patients with no bone metastases. Associations of apparent diffusion coefficient (ADC), normalized b900 diffusion-weighted imaging (nDWI) signal, and signal-weighted fat fraction (swFF) with bone marrow biopsy histological parameters were evaluated using Mann-Whitney U test and Spearman correlations...
September 12, 2017: Investigative Radiology
https://www.readbyqxmd.com/read/28887398/-64-cucl2-pet-ct-in-prostate-cancer-relapse
#6
Arnoldo Piccardo, Francesco Paparo, Matteo Puntoni, Sergio Righi, Gianluca Bottoni, Lorenzo Bacigalupo, Silvia Zanardi, Andrea DeCensi, Giulia Ferrarazzo, Monica Gambaro, Filippo Grillo Ruggieri, Fabio Campodonico, Laura Tomasello, Luca Timossi, Simona Sola, Egesta Lopci, Manlio Cabria
To evaluate the biodistribution, kinetics and radiation dosimetry of (64)CuCl2 in humans and to assess the ability of (64)CuCl2-PoPET/CT to detect prostate cancer (PCa) recurrence in patients with biochemical relapse. Methods: we prospectively evaluated 50 PCa patients with biochemical relapse after surgery or external-beam radiation therapy. All patients underwent (64)CuCl2-PET/CT, (18)F-Choline-PET/CT and multiparametric magnetic resonance imaging (mpMRI) within 15 days of each other. Experienced readers interpreted the images, and the detection rate (DR) of each imaging modality was calculated...
September 8, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28872226/prebiopsy-multiparametric-mri-based-risk-score-for-predicting-prostate-cancer-in-biopsy-naive-men-with-prostate-specific-antigen-between-4-10%C3%A2-ng-ml
#7
Durgesh Kumar Dwivedi, Rajeev Kumar, Alok Kumar Dwivedi, Girdhar S Bora, Sanjay Thulkar, Sanjay Sharma, Siddhartha Datta Gupta, Naranamangalam R Jagannathan
BACKGROUND: Risk calculators have traditionally utilized serum prostate-specific antigen (PSA) values in addition to clinical variables to predict the likelihood of prostate cancer (PCa). PURPOSE: To develop a prebiopsy multiparametric MRI (mpMRI)-based risk score (RS) and a statistical equation for predicting the risk of PCa in biopsy-naive men with serum PSA between 4-10 ng/mL that may help reduce unnecessary biopsies. STUDY TYPE: Prospective cross-sectional study...
September 4, 2017: Journal of Magnetic Resonance Imaging: JMRI
https://www.readbyqxmd.com/read/28867582/-pathological-findings-of-visible-and-non-visible-tumors-on-multiparametric-magnetic-resonance-imaging-mri-prior-to-radical-prostatectomy
#8
A Rivière, F Cornud, F Beuvon, M Sibony, P Legmann, N Barry Delongchamps
INTRODUCTION: As urologists are questioned about the overtreatment of localized prostate cancer, multiparametric MRI can diagnose significant prostate cancer thanks to targeted biopsies. However, some tumors cannot be detected by MRI. What are the pathological characteristics of those tumors? MATERIALS AND METHODS: We have selected 144 consecutive patients treated with radical prostatectomy for clinically localized prostate cancer diagnosed on systematic and targeted biopsies (Koelis(®)) according to multiparametric MRI findings...
August 31, 2017: Progrès en Urologie
https://www.readbyqxmd.com/read/28866023/where-do-trus-and-mri-guided-biopsies-miss-significant-prostate-cancer
#9
Lars Boesen, Nis Nørgaard, Vibeke Løgager, Ingegerd Balslev, Henrik S Thomsen
OBJECTIVE: To identify the location of missed sPCa lesions by transrectal ultrasound-guided (TRUSbx) and multiparametric MRI-guided biopsies (mpMRIbx) in men undergoing repeat biopsies. METHODS: 289 men with prior negative TRUSbx underwent mpMRI. The location of any suspicious lesion was registered and scored using PIRADS v1 classification according to the likelihood of being sPCa. All patients underwent repeat (re-)TRUSbx and targeted mpMRIbx (image fusion) of any suspicious lesion...
August 30, 2017: Urology
https://www.readbyqxmd.com/read/28864615/prostate-specific-membrane-antigen-ligands-for-imaging-and-therapy
#10
Matthias Eiber, Wolfgang P Fendler, Steven P Rowe, Jeremie Calais, Michael S Hofman, Tobias Maurer, Sarah M Schwarzenboeck, Clemens Kratowchil, Ken Herrmann, Frederik L Giesel
The prostate-specific membrane antigen (PSMA) is highly expressed on most prostate cancer (PC) cells. Therefore, the targeting of PSMA has become increasingly important over the last decade. Glu-urea-based PSMA ligands used for both imaging and radioligand therapy are the mainstays of the current success. For PET imaging, both (68)Ga- and (18)F-labeled agents have been successfully translated to clinical applications. Mainly retrospective cohort studies have shown a high value in the setting of biochemical recurrence, with high detection rates even in the presence of low prostate-specific antigen levels...
September 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28862352/geometric-distortion-correction-in-prostate-diffusion-weighted-mri-and-its-effect-on-quantitative-apparent-diffusion-coefficient-analysis
#11
Gabriel Nketiah, Kirsten M Selnaes, Elise Sandsmark, Jose R Teruel, Brage Krüger-Stokke, Helena Bertilsson, Tone F Bathen, Mattijs Elschot
PURPOSE: To evaluate the effect of correction for B0 inhomogeneity-induced geometric distortion in echo-planar diffusion-weighted imaging on quantitative apparent diffusion coefficient (ADC) analysis in multiparametric prostate MRI. METHODS: Geometric distortion correction was performed in echo-planar diffusion-weighted images (b = 0, 50, 400, 800 s/mm(2) ) of 28 patients, using two B0 scans with opposing phase-encoding polarities. Histology-matched tumor and healthy tissue volumes of interest delineated on T2 -weighted images were mapped to the nondistortion-corrected and distortion-corrected data sets by resampling with and without spatial coregistration...
September 1, 2017: Magnetic Resonance in Medicine: Official Journal of the Society of Magnetic Resonance in Medicine
https://www.readbyqxmd.com/read/28861291/score-3-prostate-lesions-a-gray-zone-for-pi-rads-v2
#12
REVIEW
Michele Scialpi, Eugenio Martorana, Maria Cristina Aisa, Valeria Rondoni, Alfredo D'Andrea, Giampaolo Bianchi
Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) does not offer a precise guidance on the clinical management (biopsy or not biopsy) for PI-RADS v2 score 3 lesions. Lesion volume calculated on biparametric MRI (bpMRI) [T2-weighted imaging (T2WI) and diffusion-weighted imaging (DWI)] by introducing a cut-off of 0.5 mL, allows to distinguish the lesions assigned by the multiparametric MRI (mpMRI) to the category PI-RADS v2 score 3 in two subgroups: a) Indolent or low risk lesions with volume <0...
September 2017: Turkish Journal of Urology
https://www.readbyqxmd.com/read/28856386/-focal-therapy-of-prostate-cancer
#13
R Ganzer, T Franiel, J Köllermann, T Kuru, D Baumunk, A Blana, B Hadaschik, J von Hardenberg, T Henkel, K-U Köhrmann, U-B Liehr, S Machtens, A Roosen, G Salomon, H-P Schlemmer, L Sentker, J Wendler, U Witzsch, M Schostak
The target of focal therapy (FT) in prostate cancer (PC) is partial treatment of the prostate aiming at preserving surrounding anatomical structures. The intention is to minimize typical side effects of radical treatment options combined with local tumor control. Numerous established and new technologies are used. Results of published studies showed a good safety profile, few side effects and good preservation of functional results. Oncologic long-term data are lacking so far. Photodynamic therapy (PDT) is the only technology that has been studied in a published prospective randomized trial...
August 30, 2017: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/28853167/a-urinary-biomarker-based-risk-score-correlates-with-multiparametric-mri-for-prostate-cancer-detection
#14
Rianne J Hendriks, Marloes M G van der Leest, Siebren Dijkstra, Jelle O Barentsz, Wim Van Criekinge, Christina A Hulsbergen-van de Kaa, Jack A Schalken, Peter F A Mulders, Inge M van Oort
BACKGROUND: Prostate cancer (PCa) diagnostics would greatly benefit from more accurate, non-invasive techniques for the detection of clinically significant disease, leading to a reduction of over-diagnosis and over-treatment. The aim of this study was to determine the association between a novel urinary biomarker-based risk score (SelectMDx), multiparametric MRI (mpMRI) outcomes, and biopsy results for PCa detection. METHODS: This retrospective observational study used data from the validation study of the SelectMDx score, in which urine was collected after digital rectal examination from men undergoing prostate biopsies...
August 29, 2017: Prostate
https://www.readbyqxmd.com/read/28832304/mri-targeted-biopsy-is-systematic-biopsy-obsolete
#15
Dordaneh Sugano, Abhinav Sidana, Brian Calio, Kaitlan Cobb, Baris Turkbey, Peter A Pinto
INTRODUCTION: Although prostate cancer is the most common non-cutaneous cancer in men, it is traditionally diagnosed with a non-targeted, systematic transrectal ultrasound prostate biopsy (TRUS-Bx). This technique has been demonstrated to both under-detect clinically significant (CS) cancer and over-detect clinically insignificant cancer, and performs poorly in patients with a prior negative biopsy. With recent advances in MRI technology, most prominently the advent of multiparametric MRI, MRI-targeted prostate biopsy (MRI-TB) has been gaining favor as a more accurate alternative to TRUS-Bx...
August 2017: Canadian Journal of Urology
https://www.readbyqxmd.com/read/28830850/irreversible-electroporation-for-the-treatment-of-localized-prostate-cancer-a-summary-of-imaging-findings-and-treatment-feedback
#16
Matthijs J Scheltema, Arnoud W Postema, Daniel M de Bruin, Mara Buijs, Marc R Engelbrecht, M Pilar Laguna, Hessel Wijkstra, Theo M de Reijke, Jean J M C H de la Rosette
PURPOSE: Imaging plays a crucial role in ablative therapies for prostate cancer (PCa). Irreversible electroporation (IRE) is a new treatment modality used for focal treatment of PCa. We aimed to demonstrate what imaging modalities can be used by descriptively reporting contrast-enhanced ultrasonography (CEUS), multiparametric magnetic resonance imaging (mpMRI), and grey-scale transrectal ultrasound (TRUS) results. Furthermore, we aimed to correlate quantitatively the ablation zone seen on mpMRI and CEUS with treatment planning to provide therapy feedback...
September 2017: Diagnostic and Interventional Radiology: Official Journal of the Turkish Society of Radiology
https://www.readbyqxmd.com/read/28830754/focal-therapy-eligibility-determined-by-mri-us-fusion-biopsy
#17
Nima Nassiri, Edward Chang, Patricia Lieu, Alan M Priester, Daniel J A Margolis, Jiaoti Huang, Robert E Reiter, Frederick J Dorey, Leonard S Marks, Shyam Natarajan
PURPOSE: To assess focal therapy (FT) eligibility among men receiving multiparametric magnetic resonance imaging (mpMRI) and targeted biopsy, with correlation to whole mount histology after radical prostatectomy (RP). MATERIALS AND METHODS: Subjects were selected from among the 454 men (2010-2016) with targeted biopsy-proven prostate cancer (CaP) derived from regions of interest (ROI) on mpMRI. FT eligibility was limited to a maximum Gleason score (GS) of 4+3 within ROIs with or without other foci of low-risk CaP (GS 3+3, < 4 mm)...
August 19, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28830221/pi-rads-version-2-evaluation-of-diffusion-weighted-imaging-interpretation-between-b-1000-and-b-1500-s-mm-2
#18
Mi-Ri Kwon, Chan Kyo Kim, Jae-Hun Kim
OBJECTIVES: To investigate the variability of diffusion-weighted imaging (DWI) interpretation of Prostate Imaging Reporting and Data System (PI-RADS) version 2 (v2) in evaluating prostate cancer (PCa). METHODS: One hundred fifty-four patients with PCa underwent multiparametric 3T MRI, followed by radical prostatectomy. DWI with different b values (b = 0, 100, 1000 and 1500 s/mm(2)) was obtained. Using the PI-RADS v2, two radiologists independently scored suspicious lesions in each patient and compared DWI of b = 1000 (DWI1000) with 1500 (DWI1500) s/mm(2)...
August 22, 2017: British Journal of Radiology
https://www.readbyqxmd.com/read/28830203/multimodal-image-registration-for-the-identification-of-dominant-intraprostatic-lesion-in-high-precision-radiotherapy-treatments
#19
Delia Ciardo, Barbara Alicja Jereczek-Fossa, Giuseppe Petralia, Giorgia Timon, Dario Zerini, Raffaella Cambria, Elena Rondi, Federica Cattani, Alessia Bazani, Rosalinda Ricotti, Maria Garioni, Davide Maestri, Giulia Marvaso, Paola Romanelli, Marco Riboldi, Guido Baroni, Roberto Orecchia
PURPOSE: The integration of computed tomography (CT) and multiparametric magnetic resonance imaging (mpMRI) is a challenging task in high-precision radiotherapy for prostate cancer. A simple methodology for multimodal deformable image registration (DIR) of prostate cancer patients is presented. METHODS: CT and mpMRI of ten patients were considered. Organs at risk and prostate were contoured on both scans. The dominant intraprostatic lesion was additionally delineated on magnetic resonance imaging...
August 22, 2017: British Journal of Radiology
https://www.readbyqxmd.com/read/28806263/18f-dcfbc-prostate-specific-membrane-antigen-targeted-pet-ct-imaging-in-localized-prostate-cancer-correlation-with-multiparametric-mri-and-histopathology
#20
Baris Turkbey, Esther Mena, Liza Lindenberg, Stephen Adler, Sandra Bednarova, Rose Berman, Anita T Ton, Yolanda McKinney, Philip Eclarinal, Craig Hill, George Afari, Sibaprasad Bhattacharyya, Ronnie C Mease, Maria J Merino, Paula M Jacobs, Bradford J Wood, Peter A Pinto, Martin G Pomper, Peter L Choyke
PURPOSE: To assess the ability of (N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-F-fluorobenzyl-L-cysteine) (F-DCFBC), a prostate-specific membrane antigen-targeted PET agent, to detect localized prostate cancer lesions in correlation with multiparametric MRI (mpMRI) and histopathology. METHODS: This Health Insurance Portability and Accountability Act of 1996-compliant, prospective, institutional review board-approved study included 13 evaluable patients with localized prostate cancer (median age, 62...
October 2017: Clinical Nuclear Medicine
keyword
keyword
60807
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"